A. Bruce Montgomery, MD
Dr. Montgomery is both a physician scientist and an entrepreneur who has been a leader in bringing new discoveries related to pulmonary and critical care medicine to the bedside. He has led several development teams for new medical therapies for patients with cystic fibrosis from invention to advisory board presentations, including: aztreonam lysine for inhalation (Cayston), tobramycin solution for inhalation (TOBI), and aerosolized pentamidine (NebuPent). In the 1980’s he co-invented aerosolized pentamidine, a prophylaxis for PCP, then the most common cause of death in patients with AIDS.
He has raised more than 400 million dollars in venture or public financings and is an author on 28 US patents and more than 60 peer reviewed publications. He is currently the CEO of Genoa Pharmacueticals and has been the research head or CEO of three Seattle based biotech companies.
Dr. Montgomery has served as a board member for ZymoGenetics, and is currently on the boards of three public companies Alder, Cytodyn, Xencor and two private companies Vicis and M3Bio, the latter a WSU spinout.